- Home
- FTI vs ILMN Comparison
FTI vs ILMN Comparison
Compare FTI & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTI
- ILMN
- Stock Information
- Founded
- FTI 1884
- ILMN 1998
- Country
- FTI United States
- ILMN United States
- Employees
- FTI N/A
- ILMN N/A
- Industry
- FTI Metal Fabrications
- ILMN Medical Specialities
- Sector
- FTI Industrials
- ILMN Health Care
- Exchange
- FTI Nasdaq
- ILMN Nasdaq
- Market Cap
- FTI 14.6B
- ILMN 16.0B
- IPO Year
- FTI N/A
- ILMN 2000
- Fundamental
- Price
- FTI $38.92
- ILMN $98.93
- Analyst Decision
- FTI Strong Buy
- ILMN Buy
- Analyst Count
- FTI 13
- ILMN 15
- Target Price
- FTI $39.45
- ILMN $123.67
- AVG Volume (30 Days)
- FTI 3.5M
- ILMN 1.4M
- Earning Date
- FTI 10-23-2025
- ILMN 11-03-2025
- Dividend Yield
- FTI 0.51%
- ILMN N/A
- EPS Growth
- FTI 115.07
- ILMN N/A
- EPS
- FTI 2.17
- ILMN 7.91
- Revenue
- FTI $9,504,100,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- FTI $9.68
- ILMN N/A
- Revenue Next Year
- FTI $7.53
- ILMN $2.76
- P/E Ratio
- FTI $17.96
- ILMN $12.51
- Revenue Growth
- FTI 11.75
- ILMN N/A
- 52 Week Low
- FTI $22.12
- ILMN $68.70
- 52 Week High
- FTI $39.85
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- FTI 68.21
- ILMN 50.15
- Support Level
- FTI $36.16
- ILMN $93.94
- Resistance Level
- FTI $36.53
- ILMN $100.44
- Average True Range (ATR)
- FTI 0.88
- ILMN 2.60
- MACD
- FTI 0.34
- ILMN -0.31
- Stochastic Oscillator
- FTI 83.33
- ILMN 51.39
About FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.